

THURSDAY, NOVEMBER 19TH 2026

ANU – Museum of the Jewish People, Tel Aviv

08:00-09:00 Registration, Gathering, & Exhibition

09:00-09:30 Opening Remarks & Greetings

Acute Myeloid Leukemia (AML)

Chairpersons: Ofir Wolach, MD | Yakir Moshe, MD

Session 1
09:30-11:10

09:30-09:50 | Managing Differentiation Syndrome in 2026: Steps Beyond Steroids
Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

09:50-10:05 | Triplet Strategies for AML
Courtney DiNardo, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

10:05-10:25 | Secondary AML
Stéphane de Botton, MD, Institut Gustave Roussy, Villejuif (IGR), France

10:25-10:40 | MRD in AML: highlights of the new 2025 ELN guidelines
Gail Roboz, MD, Weill Cornell Medicine, The New York Presbyterian Hospital, NY, USA

10:40-11:00 | 2026 AML Induction Therapy: What Does it Mean?
Richard Stone, MD, Dana Farber Cancer Institute, Boston, MA, USA

11:00-11:10 | AML Panel Discussion

11:10-11:30 Coffee Break & Exhibition

Acute Lymphoblastic Leukemia (ALL)

Chairperson: Irina Amitai, MD | Boaz Nachmias, MD

Session 2
11:30-12:15

11:30-11:45 | Research and Progress in B-Cell ALL at MD Anderson 2026
Hagop Kantarjian, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

11:45-12:00 | Frontline Treatment for Ph+ ALL in 2026
Nicholas J Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

12:00-12:15 | A Chemo-Free Approach Should be the New Standard for Adult Ph+ ALL. Evidence from the First Phase 3 Study
Robin Foà, MD, Department of Translational and Precision Medicine, Sapienza, University of Rome, Italy

MDS & Bone Marrow Failure Syndromes

Chairperson: Anat Gafter-Gvili, MD | Galia Stemer, MD

Session 3
12:25-13:35

12:25-12:40 | CMML Updates 2025 and Beyond
Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, USA

12:40-12:55 | New Paradigms in MDS
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

12:55-13:10 | How Do We Change the Standard of Care for Higher Risk Myelodysplastic Syndromes
David A Sallman, MD, Moffitt Cancer Center, Tampa, FL, USA

13:10-13:25 | Aplastic Anemia Management in 2026
Régis Peffault De La Tour, MD, PhD, Saint-Louis Hospital, Paris, France

13:25-13:35 | MDS & Bone Marrow Failure Syndromes Panel Discussion

13:35-14:25 Lunch & Exhibition

Myeloproliferative Neoplasms (MPN)

Chairpersons: Adi Shacham-Abulafia, MD | Moshe Yeshurun, MD

Session 4
14:25-15:25

14:25-14:40 | Myeloproliferative Neoplasms Latest Updates
Lucia Masarova, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

14:40-15:00 | Myelofibrosis and Cytopenia: Prognosis and Treatment
Mauricette Michallet, MD, Centre Léon Bérard, Lyon, France

15:00-15:15 | Systemic Mastocytosis: 2026 Update
Jason Gotlib, MD, Hematology, Stanford Cancer Center Palo Alto, Palo Alto California

15:15-15:25 | MPD Panel Discussion

Cellular Therapy

Chairperson: Avichai Shimoni, MD | Uri Greenbaum, MD

Session 5
15:25-16:00

15:25-15:40 | Beyond RIC and MAC, is there a Better Conditioning Regimen for AML?
Koen van Besien, MD, PhD, UH Seidman Cancer Center, Cleveland, OH, USA

15:40-15:55 | Bispecific CARs Targeting CD19 and CD20 for Relapsed, Refractory DLBCL
Nirav N. Shah, MD, Medical College of Wisconsin, Milwaukee, WI, USA

15:55-16:00 | Cellular Therapy Panel Discussion

16:00-16:10 Closing Remarks

FRIDAY, NOVEMBER 20TH 2026

Port Tower Hotel, Tel Aviv

08:00-08:40 Gathering

Chronic Myeloid Leukemia (CML)

Chairpersons: Pia Raanani, MD | Merav Leiba, MD

Session 6
08:40-10:15

08:40-09:00 | Should Additional Genetic Abnormalities Drive 1st Line Treatment Choices?
Delphine Rea, MD, Hopital Saint-Louis, Paris, France

09:00-09:20 | Mutations in CML: the Good, the Bad, the Ugly
Simona Soverini, PhD, Alma Mater Studiorum Universita di Bologna, Italy

09:20-09:40 | Present Routine Clinical Management of CML Patients in Italy and how it Will Probably Change in 2026
Giuseppe Saglio, MD, University of Turin, Italy

09:40-10:00 | Optimizing Quality of Life in CML and CMPN
Philipp Le Coutre, MD, Charité – Universitätsmedizin Berlin, Germany

10:00-10:15 | CML Panel Discussion

10:15-10:35 Coffee Break

Lymphomas and Plasma Cell Dyscrasias

Chairpersons: Lotem Harel, MD | Ronit Gurion, MD

Session 7
10:35-12:05

10:35-10:50 | Next Steps for Hodgkin Lymphoma
Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

10:50-11:10 | Amyloidosis: when Dara Fails What's Next?
Morie Gertz, MD, Mayo Clinic Rochester, MN, USA

11:10-11:25 | TBC
Steve Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

11:25-11:40 | Relapse FL: CAR-T or Bispecific Antibody
Gilles Salles, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

11:40-11:55 | Risk adapted therapy in multiple myeloma
Angela Dispenzieri, MD, Mayo Clinic Rochester, MN, USA

11:55-12:05 | Lymphomas and Plasma Cell Dyscrasias Panel Discussion

Chronic Lymphocytic Leukemia (CLL)

Chairpersons: Liron Hofstetter, MD | Yair Herishanu, MD

Session 8
12:05-13:10

12:05-12:25 | Diagnosis and New Treatment Options in Richter Transformation
Barbara Eichhost, MD, University Hospital Cologne, Germany

12:25-12:40 | Frontline Treatment of Chronic Lymphocytic Leukemia in 2026
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

12:40-13:00 | Refractory CLL in 2026: Diagnostic and Therapeutic Approaches
Jan A. Burger, MD, University of Texas MD Anderson Cancer Center, Houston, TX, USA

13:00-13:10 | CLL Panel Discussion

13:10-13:15 Closing Remarks

We would like to thank our Sponsors

PLATINUM

NOVARTIS

GOLD

MEDISON

Roche

Lilly

astellas

AstraZeneca

GILEAD

Johnson&Johnson

GSK

NEOPHARM ISRAEL

abbvie

Takeda